Find Drugs for Pulmonary/Respiratory Diseases in Phase I Clinical Development in UNITED STATES

Lead Product(s): PUR1800

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Nocion Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 06, 2020

Details:

The collaboration will leverage Pulmatrix's iSPERSEâ„¢ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.

Lead Product(s): PUR1800

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Johnson & Johnson Enterprise Innovation

Deal Size: $100.2 million Upfront Cash: $7.2 million

Deal Type: Licensing Agreement January 02, 2020

Details:

Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors,the intended for development in lung cancer interception. the ongoing Phase 1b study of RV1162/PUR1800 in stable COPD patients.